Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Relapsed or refractory chronic lymphocytic leukemia.
Patients must have either intermediate or high risk chronic lymphocytic leukemia according to the Rai Staging System.
Must have failed at least 1 prior chemotherapy regimen (at least 1 of which included fludarabine) for CLL.
No prior therapy within 4 weeks prior to entering the study. Patients must have fully recovered from the acute effects of prior therapy.